MINIject interim three-year data to be presented at WGC-2021

Interim three-year data on iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device MINIjectTM will be presented at the World Glaucoma Congress WGC-21, virtually hosted by the Japan Glaucoma Society between 30th June and 3rd July.

Read more

Prof. Dr Christoph Hirneiß presents MINIject at DOC 2021 digital

The DOC (Deutsche Gesellschaft für Ophthalmochirurgie e.V.) are holding their 33rd International Congress of German Ophthalmic Surgeons as a digital event this year from 17 to 19 June 2021. The congress includes an extensive programme with scientific sessions on glaucoma surgery.

Read more

MINIject presented at MIGS Symposium 2021

MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) device, will be presented in two lectures at the upcoming MIGS Symposium 2021 on Saturday, 17th April from 11:00AM to 2:30PM CET.

Read more

MINIject on best-in-class trajectory at Innovation Summit

Med-tech innovation summit logo


CEO Michel Vanbrabant presented to an audience of institutional and strategic investors at the Innovation Summit Dublin on 13-15 April.

Read more

STAR-II promising results in Ophthalmology Times

The six and 12-month results from the STAR-II trial on MINIjectTM have been reported in the latest issue of Ophthalmology Times.

Read more

iSTAR Medical 2021 roadmap at BioCapital Europe

CEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.

Read more

MINIject STAR-II 12-month trial results at AGS

The 12-month results from the European STAR-II trial of iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the American Glaucoma Society (AGS) meeting.

Read more

MINIject in Ophthalmology Times Europe

An article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.
Read more

MINIject in Glaucoma Physician journal

In the latest issue of Glaucoma Physician, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM features as a prominent solution to unlock the potential of the suprachoroidal space in glaucoma treatment.

Read more

MINIject’s 2020 results at EGS

The 2020 results from trials of minimally invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the upcoming European Glaucoma Society (EGS) annual meeting on 12-13 December. The consistently positive data showed outstanding results of intraocular pressure (IOP) and medication reduction in patients with open angle glaucoma, and a positive safety profile across trials.

The final two-year outcomes from the STAR-I clinical trial will be presented by Professor Doctor Philippe Denis, one of the trial investigators and Chair of the Department of Ophthalmology of Croix-Rousse University Hospital of Lyon, France. The one-year data from the European STAR-II trial will be presented by Professor Doctor Katrin Lorenz, Head of the Clinical Study Center at the Eye Clinic, Mainz University Medical Centre, Germany.

“In 2020, the STAR-I and STAR-II results brought very promising news in minimally invasive glaucoma surgery. They consistently confirmed that MINIject is a remarkably effective treatment option for patients, while maintaining very positive safety outcomes,” explained Professor Denis, who was also an investigator in the STAR-II trial. “These data bring promise that soon an optimal, effective and longer-lasting treatment for patients with glaucoma may be possible, while avoiding the risks associated with more invasive eye surgery,” he added.

Both data sets will be presented as on-demand video presentations during the congress and will be available to attendees for three months, and permanently to EGS members. To register: http://www.egs2020.org/node/14